The EP4 antagonist E7046 therapy increased the population of intratumoral effector CD8+ T cells, inhibited myeloid MDSC activation, and suppressed the polarization of macrophages to M2-like properties in a CT26 mouse colon cancer model. This evidence concerns the gene CD8A and colonic neoplasm.